MAL-LAD

MAL-LAD, or MALLAD, also known as METAL-LAD or METALLAD, as well as 6-methallyl-6-nor-LSD, is a serotonin receptor modulator of the lysergamide family related to lysergic acid diethylamide (LSD).^[1][2]

Other namesMALLAD; METAL-LAD; METALLAD; 6-Methallyl-6-nor-LSD; N,N-Diethyl-6-(2-methylprop-2-en-1-yl)-9,10-didehydroergoline-8β-carboxamide

Drug classSerotonin receptor agonist

ATC code

• None

FormulaC₂₃H₂₉N₃O

Quick facts Clinical data, Other names ...

MAL-LAD

Clinical data
Other names	MALLAD; METAL-LAD; METALLAD; 6-Methallyl-6-nor-LSD; N,N-Diethyl-6-(2-methylprop-2-en-1-yl)-9,10-didehydroergoline-8β-carboxamide
Drug class	Serotonin receptor agonist
ATC code	None
Identifiers
IUPAC name (6aR,9R)-N,N-Diethyl-7-(2-methylprop-2-en-1-yl)-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
Chemical and physical data
Formula	C23H29N3O
Molar mass	363.505 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCN(C(=O)[C@H]1CN(CC(=C)C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC
InChI InChI=1S/C23H29N3O/c1-5-25(6-2)23(27)17-10-19-18-8-7-9-20-22(18)16(12-24-20)11-21(19)26(14-17)13-15(3)4/h7-10,12,17,21,24H,3,5-6,11,13-14H2,1-2,4H3/t17-,21-/m1/s1 Key:CMBLBLPHJKCTIR-DYESRHJHSA-N

Close

The drug acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT_2A receptor among others.^[1][2] It is also a dopamine receptor agonist, though unlike other lysergamides, does not show activity at the dopamine D₁ and D₅ receptors.^[2] MAL-LAD does not appear to have been assessed in animal tests of psychedelic-like activity such as drug discrimination.^[1]

MAL-LAD was first described in the scientific literature by Andrew Joseph Hoffman of the lab of David E. Nichols at Purdue University by 1987.^[1] It was subsequently further described by a group of researchers that included Nichols and other colleagues in 2025.^[2] The drug is not a controlled substance in Canada as of 2025.^[3]